News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Vertex Pharmaceuticals Incorporated 1st-Quarter Loss Widens on Expenses
April 17, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
NEW YORK, April 16 (Reuters) - Vertex Pharmaceuticals Inc. reported a wider first-quarter loss on Thursday due to high drug development costs and acquisition related and restructuring expenses.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Vertex Pharmaceuticals
MORE ON THIS TOPIC
Funding
Sofinnova, Sanofi alum unveil Bionyra with $165M and next-gen immunology assets
June 22, 2026
·
2 min read
·
Gabrielle Masson
Business
Sanofi’s R&D head exits, with AI biotech Xaira’s exec stepping in
June 22, 2026
·
1 min read
·
Gabrielle Masson
Mergers & acquisitions
AbbVie strikes $10.9B Apogee buy to challenge juggernaut Dupixent
June 22, 2026
·
2 min read
·
Tristan Manalac
ALS
Nura raises $73.8M to target ALS through a unique target
June 22, 2026
·
4 min read
·
Michael Gibney
